Adamantane-Resistant Influenza Infection During the 2004–05 Season

Mahbubur Rahman,*1 Rick A. Bright,†2 Burney A. Kieke,* James G. Donahue,* Robert T. Greenlee,* Mary Vandermause,* Amanda Balish,† Angela Foust,† Nancy J. Cox,† Alexander I. Klimov,† David K. Shay,† and Edward A. Belongia*

Adamantane-resistant influenza A is an emerging problem, but infections caused by resistant and susceptible viruses have not been compared. We identified adamantane resistance in 47% of 152 influenza A virus (H3N2) isolates collected during 2005. Resistant and susceptible viruses caused similar symptoms and illness duration. The prevalence of resistance was highest in children.

During the past 4 decades, antiviral drug therapy has been a useful strategy for both prophylaxis and treatment of influenza A (1,2). The most widely used drugs have been 2 adamantane derivatives (amantadine and rimantadine), which are effective for prophylaxis and reduce illness duration if started within 48 hours after symptom onset (3,4). These drugs block the M2 ion channel protein, preventing viral replication (5). From 1997 through 2004, few influenza A (H3N2) isolates were resistant to adamantanes, although resistance among isolates from Asia increased substantially in 2003 (6). In the United States, the proportion of influenza A (H3N2) isolates with adamantane resistance was 0.8%–2.2% during this period and 11% in the 2004–05 influenza seasons. However, in the 2005–06 season, >90% of influenza A (H3N2) isolates from patients in 26 states contained a mutation conferring resistance to adamantane drugs (7).

Ferret models suggest that virulence is not increased by adamantane resistance in influenza A (H3N2) infections (8), although experimental studies with recombinant influenza (H1N1) in mice have suggested that the mortality rate is increased by a double mutation conferring adamantane resistance (9). Little is known regarding clinical effects in humans infected with adamantane-resistant influenza viruses. We compared clinical and demographic characteristics of patients infected with either adamantane-susceptible or -resistant strains of influenza A during the 2004–05 season.

The Study

Study participants were derived from a study of influenza vaccine effectiveness conducted within a 14–Zip code region surrounding Marshfield, Wisconsin, during January–March 2005. Eligible participants included children 6–23 months of age, adults ≥65 years of age, and persons 24 months–64 years of age with a high-risk medical condition. Research coordinators recruited eligible patients and obtained samples for influenza culture during inpatient and outpatient encounters for acute respiratory illness. Each participant (or parent) completed a short interview form to assess symptoms and onset date, and culture-confirmed patients were contacted again to determine the illness recovery date. The study was approved by the Marshfield Clinic institutional review board, and all participants provided written informed consent.

Figure. Results of patient recruitment and influenza cultures. *One isolate was not characterized.

*Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA; and †Centers for Disease Control and Prevention, Atlanta, Georgia, USA

†Current affiliation: University of Texas Medical Branch, Galveston, Texas, USA

3Current affiliation: Novavax, Malvern, Pennsylvania, USA
Influenza virus was isolated by inoculation and incubation in monolayered rhesus monkey kidney cells. Cultures were examined for cytopathic effect, and cultures showing no cytopathic effect were tested twice for hemagglutination titers. Influenza A and B were confirmed by immunofluorescence (Chemicon International, Inc., Temecula, CA, USA). All influenza A isolates were tested for adamantane resistance at the Centers for Disease Control and Prevention (CDC). Procedures for RNA extraction and pyrosequencing have been previously described (7). A medical record review was performed to assess any use of antiviral drugs by influenza A patients from 60 days before through 14 days after the enrollment date.

Univariate comparisons were performed, and crude and adjusted prevalence ratios were computed to evaluate the association between adamantane resistance and age, gender, vaccination status, date of clinical encounter, and presence of a high-risk medical condition. Enrollment dates were grouped into 4 consecutive 3-week periods beginning January 3, 2005. The referent period was the second 3-week period when the number of influenza cases peaked.

Table 1. Clinical features of patients with adamantane-resistant or -susceptible influenza A, 2004–05 season

| Clinical feature                                           | Adamantane-resistant influenza, n = 72 | Adamantane-susceptible influenza, n = 80 | p value* |
|-----------------------------------------------------------|----------------------------------------|------------------------------------------|----------|
| Median duration of illness†                                | 12 days                                 | 13 days                                  | 0.96     |
| No. (%) hospitalized                                      | 7 (10)                                 | 9 (12)                                   | 0.74     |
| No. (%) fully recovered at time of follow-up interview    | 63 (88)                                | 65 (81)                                  | 0.29     |
| Median no. symptoms‡                                       | 9                                      | 8                                        | 0.59     |
| No. (%) receiving antiviral treatment§                    | 15 (21)                                | 31 (39)                                  | 0.02     |
| Median time from symptom onset to healthcare encounter    | 3 days                                  | 2 days                                   | 0.34     |
| Single symptom, no. (%)‡                                   |                                        |                                          |          |
| Fever                                                     | 34 (69)                                | 52 (74)                                  | 0.56     |
| Cough                                                     | 48 (98)                                | 68 (97)                                  | 0.78     |
| Headache                                                  | 41 (84)                                | 53 (76)                                  | 0.29     |
| Muscle pain                                               | 37 (76)                                | 45 (64)                                  | 0.57     |
| Nasal congestion                                           | 40 (82)                                | 54 (77)                                  | 0.55     |
| Hoarseness                                                | 35 (71)                                | 55 (79)                                  | 0.37     |
| Fatigue                                                    | 45 (92)                                | 66 (94)                                  | 0.72     |
| Ear pain                                                   | 16 (33)                                | 24 (34)                                  | 0.85     |
| Sore throat                                                | 29 (59)                                | 40 (57)                                  | 0.82     |
| Difficulty breathing                                      | 28 (57)                                | 35 (50)                                  | 0.44     |
| Wheezing                                                   | 25 (51)                                | 42 (60)                                  | 0.33     |
| Nausea                                                     | 16 (33)                                | 27 (39)                                  | 0.51     |
| Vomiting                                                   | 10 (20)                                | 9 (13)                                   | 0.27     |
| Diarrhea                                                   | 12 (24)                                | 15 (21)                                  | 0.70     |
| Rash                                                       | 2 (4)                                  | 2 (3)                                    | 1.00     |
| Combined symptoms, no. (%)‡                                |                                        |                                          |          |
| Fever and cough                                            | 33 (67)                                | 52 (74)                                  | 0.41     |
| Fever and headache                                         | 31 (63)                                | 43 (61)                                  | 0.84     |
| Fever, cough, and headache                                 | 30 (61)                                | 43 (61)                                  | 0.98     |
| Fever and muscle pain                                      | 29 (59)                                | 39 (56)                                  | 0.71     |
| Fever, headache, and muscle pain                           | 27 (55)                                | 35 (50)                                  | 0.58     |
| Fever, headache, muscle pain, and cough                    | 26 (53)                                | 35 (50)                                  | 0.74     |

*χ², Fisher exact, or Wilcoxon rank sum tests performed as appropriate.
†Based on 128 influenza A patients who had recovered fully at the time of follow-up interview.
‡Children 6 to 23 months of age were excluded from the numerator and denominator for symptoms.
§One patient had received antiviral treatment prior to influenza culture.
and the distribution of individual symptoms did not differ significantly. Forty-five patients received antiviral therapy (37 adamantanes, 8 oseltamivir), but only 1 was treated with amantadine before influenza culture was obtained. Clinical features and duration of illness were similar whether or not patients received amantadine therapy. In a multivariable model that included patients of all ages, amantadine resistance was not associated with gender, time of clinical encounter, or influenza vaccination status (Table 2). Children 6–23 months old without a high-risk medical condition were significantly more likely to be infected with amantadine-resistant influenza A than were adults ≥65 years of age who had a high-risk condition. In a secondary analysis, no association was found between amantadine resistance and number of symptoms, duration of illness, or hospitalization.

Conclusions

This study provides epidemiologic evidence that the point mutation (S31N) conferring amantadine resistance has not altered influenza A (H3N2) virulence as measured by clinical symptoms and duration of illness. Hospitalization rates were also similar, although the power to detect a difference was low. These results are consistent with prior research in ferrets, which demonstrated that virulence was similar for amantadine-resistant and -susceptible influenza A (H3N2) isolates (8). The source population for this study included persons who were eligible for influenza vaccination based on age group or the presence of a high-risk medical condition. Consequently, participants were more likely to experience influenza complications relative to the general population. The absence of any difference in clinical severity in this higher risk population provides some assurance that amantadine resistance will not affect overall influenza morbidity.

Factors contributing to rapid emergence of amantadine-resistant influenza viruses are not fully known. Resistance has been observed in a variety of outbreak and institutional settings for many years (10–12) but did not spread into the general population until recently (6,7). The proportion of human influenza A (H3N2) isolates with amantadine resistance increased dramatically in People’s Republic of China and Taiwan in 2003 (6). However, the degree to which the spread of resistant viruses from Asia contributed to the rapid escalation of amantadine resistance in the United States is uncertain.

The 2004–05 influenza season provided an opportunity to learn more about the epidemiology of amantadine resistance during a period when drug resistance was increasing in Wisconsin but was not yet universal. Children had the highest risk of acquiring an amantadine-resistant influenza infection and are an important reservoir for transmission of influenza to adult household members and the community (13). Still, we cannot explain why children were preferentially infected with amantadine-resistant strains in 2004–05. Only 1 patient was treated with amantadine before enrollment. The higher prevalence of resistance in children was therefore not attributable to individual amantadine use. There may have been multiple introductions of amantadine-resistant influenza viruses from other geographic areas during the 2004–05 season. This phenomenon was described in a recent phylogenetic analysis of influenza A

| Table 2. Demographic features of patients with amantadine-resistant or -susceptible influenza A, 2004–05 season* |
|------------------------------------------------------|
| **Variable**                                        | **No. (%)** resistant isolates, n = 72 | **No. (%)** susceptible isolates, n = 80 | **Unadjusted prevalence ratio (95% CI)** | **Adjusted prevalence ratio (95% CI)** |
| Age and high-risk status†                           |                                       |                                          |                                       |                                       |
| 6–23 mo without high risk                           | 20 (74.1)                             | 7 (25.9)                                | 2.0 (1.3–3.0)                          | 2.1 (1.4–3.1)                          |
| 6–23 mo with high risk                              | 3 (50.0)                              | 3 (60.0)                                | 1.3 (0.6–3.2)                          | 1.4 (0.5–3.5)                          |
| 2–17 y with high risk                               | 8 (61.5)                              | 5 (38.5)                                | 1.7 (0.9–2.9)                          | 1.4 (0.8–2.4)                          |
| 18–49 y with high risk                              | 7 (36.8)                              | 12 (63.2)                               | 1.0 (0.5–2.0)                          | 0.9 (0.5–1.9)                          |
| 50–64 y with high risk                              | 8 (38.1)                              | 13 (61.9)                               | 1.0 (0.5–2.0)                          | 1.0 (0.6–1.9)                          |
| ≥65 y without high risk                             | 7 (46.7)                              | 8 (53.3)                                | 1.3 (0.7–2.4)                          | 1.2 (0.7–2.3)                          |
| ≥65 y with high risk                                | 19 (37.2)                             | 32 (62.8)                               | Referent group                         | Referent group                         |
| Sex                                                  |                                       |                                          |                                       |                                       |
| Male                                                 | 37 (50.7)                             | 36 (49.3)                               | 1.1 (0.8–1.6)                          | 1.1 (0.8–1.5)                          |
| Female                                               | 35 (44.3)                             | 44 (55.7)                               | Referent group                         | Referent group                         |
| Dates of clinical encounter                         |                                       |                                          |                                       |                                       |
| 2005 Jan 3–23                                       | 10 (47.6)                             | 11 (52.4)                               | 0.9 (0.5–1.4)                          | 0.9 (0.5–1.5)                          |
| 2005 Jan 24–Feb 13                                  | 44 (55.0)                             | 36 (45.0)                               | Referent period                        | Referent period                        |
| 2005 Feb 14–Mar 6                                   | 15 (35.7)                             | 27 (64.3)                               | 0.6 (0.4–1.0)                          | 0.6 (0.4–1.0)                          |
| 2005 Mar 7–25                                       | 3 (33.3)                              | 6 (66.7)                                | 0.6 (0.2–1.6)                          | 0.5 (0.2–1.3)                          |
| Received 2004–05 influenza vaccine?                  |                                       |                                          |                                       |                                       |
| Yes                                                  | 45 (42.9)                             | 60 (57.1)                               | 0.7 (0.5–1.0)                          | 0.8 (0.6–1.1)                          |
| No                                                   | 27 (57.4)                             | 20 (42.6)                               | Referent group                         | Referent group                         |

*CI, confidence interval.
†For the multivariate model, a composite variable was created based on age and the presence or absence of a high-risk medical condition as defined by Advisory Committee on Immunization Practices criteria.
(H3N2) isolates from New York state over a 9-year period (14). The analysis suggested that viral evolution within epidemic seasons is dominated by random importation of distinct viral strains from other geographic areas.

CDC continues to recommend that adamantane drugs not be used for influenza treatment in the United States. Given the recent emergence of oseltamivir-resistant influenza A and B infections (15,16), ongoing monitoring of influenza virus susceptibility to adamantanes and neuraminidase inhibitors is essential.

Acknowledgments
We thank the following persons who contributed to this project at the Marshfield Clinic Research Foundation: Richard Berg, Carol Beyer, Marilyn Bruger, Autumn Deedon, Theresa Esser, Jayne Frahmann, Julie Friedhoff, Gregg Greenwald, Deborah Hilgenmann, Kate Konitzer, Jordon Ott, Melanie Rayhorn, Sonia Stratman, Sandra Strey, and Kari Weik. We also thank Henrietta Hall, Jan Mahry, Theresa Wallis, and Xiyan Xu from the Influenza Branch Strain Surveillance Section at CDC for their contributions.

Funding for this research was provided by a cooperative agreement with CDC (1 U01 CI000192-01).

Dr Rahman was a postdoctoral fellow at the Marshfield Clinic Research Foundation, Marshfield, Wisconsin, at the time of this study. He is currently affiliated with the University of Texas Medical Branch in Galveston.

References
1. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307: 580–4.
2. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am. 1987;1:459–78.
3. Younkin SW, Betts RF, Roth FK, Douglas RG Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother. 1983;23:577–82.
4. Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 1989;11: 27–40.
5. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993;67:5585–94.
6. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of amantadine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175–81.
7. Bright RA, Shyu DK, Shu B, Cox NJ, Klimov AI. Amantadine resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891–4.
8. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis. 1991;164:969–72.
9. Abed Y, Goyette N, Bolvin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother. 2005;49:556–9.
10. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696–702.
11. Degelau J, Somani SK, Cooper SL, Guay DR, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med. 1992;152:390–2.
12. Mast EE, Harmon MW, Gravenstein S, Wu SP, Arden NH, Circo R, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol. 1991;134:988–97.
13. Hurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000;284:1677–82.
14. Nelson MI, Simonsen L, Viboud C, Miller MA, Taylor J, George KS, et al. Stochastic processes are key determinants of short-term evolution in influenza A virus. PLoS Pathogens. 2006;2:e125.
15. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435–42.
16. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–65.

Address for correspondence: Edward A. Belongia, Epidemiology Research Center (ML2), Marshfield Clinic Research Foundation 1000 N Oak Ave, Marshfield, WI 54449, USA; email: belonging.edward@marshfieldclinic.org